New Treatment on the Horizon for Uveitis
Posted on Tue, 04 Aug 2009 12:16:35 by Kristian Hurley
Check out this news spotlight on a new drug to treat uveitis patients currently in the clinical trial stage. The promising product is said to be a corticosteroid-sparing agent for the treatment of non-infectious uveitis. According to the manufacturer, Lux Biosciences, "Luveniq (LX211) will be the first steroid-sparing agent to be commercialized for uveitis in the United States and most international markets."
Click Here for video featuring LX211
|
|
|
No one has made a comment yet. Be the first, post a comment.
|
